Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pearl Clear all

Conditions: Schizophrenia
Interventions: Lurasidone, Matching Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Springdale, Arizona • Little Rock, Arkansas • Cerritos, California + 36 more

Conditions: Non Small Cell Lung Carcinoma NSCLC
Interventions: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Class IV Angina
Interventions: Not listed
Lead sponsor: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Vaginal Microbiota
Interventions: Tampon A, Tampon B; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ametropia
Interventions: Sapphire, Pearl; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 6
States / cities: San Diego, California • Torrance, California • Denver, North Carolina + 3 more

Conditions: RSV Immunisation
Interventions: RSVt Vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 21 Months
Enrollment: 6,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more

Conditions: MPS I, MPS II, MPS IVA, MPS VI, Mps VII, Gaucher Disease, Type 2, Gaucher Disease, Type 3, Pompe Disease Infantile-Onset, Wolman Disease
Interventions: Aldurazyme (laronidase); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab intravitreal injection; Drug
Lead sponsor: Hawaii Pacific Health; Other
Eligibility: 25 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Honolulu, Hawaii • ‘Aiea, Hawaii

Conditions: Survival of Probiotics During GI Transit, GI Symptoms
Interventions: Acidophilus pearls, Hard shell gelatin capsules; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Osteoporosis
Interventions: lasofoxifene, placebo; Drug · Other
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 60 Years to 80 Years · Female only
Enrollment: 8,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 48
States / cities: Birmingham, Alabama • La Jolla, California • Palm Desert, California + 29 more

Conditions: HIV
Interventions: Care management; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anus Neoplasms
Interventions: AIJP (Arnebia Indigo Jade Pearl), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 99 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Quetiapine fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 56
States / cities: Phoenix, Arizona • El Centro, California • Irvine, California + 53 more

Conditions: Dietary Supplements
Interventions: Muscadine grape seed supplement; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Safety and Tolerability in Healthy Volunteers
Interventions: Tampon; Device
Lead sponsor: Lyv Life Inc. (dba: Cora); Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Neonatal Respiratory Distress Related Conditions, Meconium, Perinatal Morbidity, Neonatal Acidosis, Cord Blood, Neonatal Brain Injury, Maternal Morbidity, Mechanical Ventilation, CPAP, Surfactant, Perinatal Death, Amnioinfusion, NICU Admission
Interventions: Intrauterine pressure catheter, Standard obstetric care at discretion of delivery provider; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pelvic Floor Disorder, Loneliness, Postpartum, Mental Health, Depression, Peritraumatic Distress, Women, Artificial Intelligence (AI), Chatbot
Interventions: Generative artificial intelligence (genAI) postpartum chatbot, Standard of Care (SOC); Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions: Pearl millet couscous - made in Senegal, Pearl millet couscous - made in USA, Pearl millet thick porridge, Wheat couscous, White rice; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Systemic Lupus Erythematosus
Interventions: A-623, Placebo Comparator; Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 11 more

Conditions: Caries, Unsatisfactory or Defective Restoration of Tooth
Interventions: Placement of restoration; Device
Lead sponsor: Heraeus Kulzer GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Schizophrenia
Interventions: Lurasidone HC1, Quetiapine XR; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 27
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 21 more

Conditions: Hyperkalemia, End Stage Renal Disease
Interventions: Patiromer Oral Powder Product; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Violence and Victimization
Interventions: PEARL (Photo-experiencing and Reflective Listening); Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congestive Heart Failure
Interventions: Monitoring on heart failure therapy; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

PEARL Schizophrenia Maintenance

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

The PEARL 8.0 Post-Approval Study

Examining the Impact of Tampon Use on the Vaginal Microbiota

Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Acidophilus Pearls Fecal Recovery Study

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care

Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

Muscadine Grape Seed Supplementation and Vascular Function

Safety and Tolerability of an Ultra Absorbency Menstrual Tampon Compared to a Commercially Marketed Tampon

Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure

Postpartum Education Via Artificial Intelligence for Recovery and Loneliness: A Randomized Controlled Trial

Digestive Properties of Carbohydrate-based Foods

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Comparison of 2 Different Resin Based Filling Materials in Posterior Teeth - a Multicenter Study

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

Photo-experiencing and Reflective Listening (PEARL) to Promote Healing Engagement for Survivors of Violence

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study